The Biostatistics and Bioinformatics Core facility provides the statistical and computational support for all Gl cancer SPORE investigators. The Core will support consultation and collaboration on all aspects of study design, database development and quality control, and analysis and interpretation of data. The statisticians and bioinformatics scientists participating in the Biostatistics and Bioinformatics Core have been chosen for their broad range of expertise and experience in clinical trials, laboratory experiments, genetics and genomics research, computational biology and epidemiology studies. Dr. Dianne Finkelstein and Dr. Hui Zheng have extensive experience as statisticians within the comprehensive cancer center and cooperative oncology group settings. Dr. John Quackenbush directs the Centerfor Cancer Computational Biology at the Dana-Farber Cancer Institute (DFCI) and has extensive experience in genomics and computational biology. Dr. Barbara Weir and Nicholas Stransky are computational biologists who have deep expertise in the development and deployment of methods to analyze and integrate genomic datasets. Collectively these individuals have affiliations at Massachusetts General Hospital (MGH), DFCI, Harvard Medical School (HMS), Harvard School of Public Health (HSPH) and the Broad Institute of Harvard and MIT. However, their SPORE collaborations will be based on areas of expertise and need and will involve investigators from several of the affiliate institutions. The Biostatistics and Bioinformatics Core members have participated regularly in the planning meetings where the scientific goals and research methods of the SPORE projects were discussed.
The specific aims of this core facility are to;1: Provide ready access to statistical and bioinformatics expertise and computing consultation to the Gl cancer SPORE program;2: Provide biostatistical/bioinformatics expertise forthe planning, analysis and reporting of laboratory experiments, epidemiology studies and clinical trials;3: Advise and support SPORE investigators and their data collectors (technicians, nurses, data managers, etc.) in the areas of data form design, data collection, record abstraction, computerization, database designing and management, and data quality control;4: Provide support for the development of integrative computational models to facilitate the analysis and interpretation of complex genomic datasets;5: Provide the scientific computing expertise required to meet the data management and analytical needs of Gl cancer SPORE investigators.

Public Health Relevance

During the last 20 years, the development of new statistical methodology for cancer research has resulted in an expanded role for the statistician in the research process and a higher standard for scientific evidence in a study. The Biostatistics and Bioinformatics Core facility provides the statistical and computational support for all Gl cancer SPORE investigators. The Core will support consultation and collaboration on all aspects of study design, database development and quality control, and analysis and interpretation of data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127003-07
Application #
8933246
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Program Officer
Agarwal, Rajeev K
Project Start
2007-04-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$188,057
Indirect Cost
$60,788
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Babic, A; Schnure, N; Neupane, N P et al. (2018) Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 9:145
Lopes-Ramos, Camila M; Kuijjer, Marieke L; Ogino, Shuji et al. (2018) Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism. Cancer Res 78:5538-5547
Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230
Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822
Katona, Bryson W; Yurgelun, Matthew B; Garber, Judy E et al. (2018) A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med 20:1324-1327
Jeon, Jihyoun; Du, Mengmeng; Schoen, Robert E et al. (2018) Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology 154:2152-2164.e19
Kosumi, Keisuke; Hamada, Tsuyoshi; Koh, Hideo et al. (2018) The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. Am J Pathol 188:2839-2852
Aguirre, Andrew J (2018) Refining Classification of Pancreatic Cancer Subtypes to Improve Clinical Care. Gastroenterology 155:1689-1691
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wang, Xiaoliang; Chan, Andrew T; Slattery, Martha L et al. (2018) Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk. Cancer Res 78:4790-4799

Showing the most recent 10 out of 590 publications